Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

The latest in immuno research, from the discovery & development of cell & antibody therapies through to omics-based approaches and clinical case studies

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Therapeutic Modalities

Xdrop® Encapsulate cells, DNA, and more with this benchtop instrument

Xdrop is a unique, user-friendly microfluidics instrument for preparing living mammalian or microbial cells, organelles, DNA, or other biological material for high-resolution downstream analyses.
Read More
Therapeutic Modalities

Rapidly quantifying active killer cells using an Xdrop® single-cell format assay based on double-emulsion droplets

Bulk assays of killer cell activity mask the heterogeneity of the individual cells‘ actual cytotoxicity. This Xdrop single-cell format assay for quantifying natural killer cells reveals the active cells and enables their retrieval and expansion.
Read More
Therapeutic Modalities

Revealing and retrieving highly potent IFN-? secretors using an Xdrop® single-cell format workflow based on double-emulsion droplets

Bulk functional assays of immune cells miss highly potent cells within the population. This Xdrop single-cell format workflow for IFN-? secretion assessment reveals these highly potent individual cells, enabling their retrieval and expansion.
Read More
Therapeutic Modalities

Quantifying individual cells that secrete IFN-?, TNF-?, or both cytokines in a single-cell, drop®-based workflow

This Xdrop workflow enables rapid, multiplex quantification of the individual immune cells in a population that are secreting one or more cytokines. The results for single-cell format multiplex and singleplex assay concurred and were reproducible.
Read More
Therapeutic Modalities

Cancer Vaccines: Analysing the Resurgence

Looking at the past, present, and future of cancer vaccines. What are the reasons for past failings? And what's the next step for their development?
Read More
Therapeutic Modalities

App Note: CAR-T: A Promising Cell Therapy for Cancer Treatment

This application note by Sino Biological explores the key steps involved in CAR-T production to provide insights into the challenges that may impede successful CAR-T therapy.
Read More
Therapeutic Modalities

NK Cell Therapies and Their Promising Possibilities

Considering the potential of natural killer (NK) cells as immunotherapies for cancer treatment and the various methods being utilised to overcome cancer cells' resistance to NK cells.
Read More
Therapeutic Modalities

Axion Biosystems: In vitro Potency Assays for Immune Cell-Mediated Killing with the Maestro Z

Immunotherapy harnesses the power of the innate and adaptive immune system in various ways to seek out and attack cancer.
Read More
Therapeutic Modalities

Axion Biosystems: Quantifying NK-mediated Cytolysis of Glioblastoma in vitro with Maestro Z

Immunotherapy aims to harness and enhance the body’s immune system to fight cancer.
Read More
Therapeutic Modalities

GD2 CAR-T cells engineered using retroviral transduction or CRISPR editing exhibit strong cytolytic potency against glioma stem cells

Axion BioSystems’ Maestro Z platform offers impedance-based cell analysis for real-time, label-free monitoring of cell viability, morphology, cytolysis, and signaling.
Read More
Therapeutic Modalities

Axion Biosystems: Antibody-dependent Cellular Cytotoxicity of Natural Killer Cells

Trastuzumab promotes natural killer cell activation through antibody-dependent cellular cytotoxicity (ADCC).
Read More
Therapeutic Modalities

Axion Biosystems: CAR T Cell Potency Assessment with 3D Cancer Spheroid Models

The solid tumor microenvironment poses a significant challenge to immune therapies like CART cells.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things immuno